NorthCrest Asset Manangement LLC Acquires 1,843 Shares of United Therapeutics Corporation $UTHR

NorthCrest Asset Manangement LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 32.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,537 shares of the biotechnology company’s stock after buying an additional 1,843 shares during the period. NorthCrest Asset Manangement LLC’s holdings in United Therapeutics were worth $3,691,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Clearstead Advisors LLC raised its holdings in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares in the last quarter. Bessemer Group Inc. grew its stake in United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 28 shares in the last quarter. Archer Investment Corp increased its position in shares of United Therapeutics by 9.5% during the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 31 shares during the last quarter. F m Investments LLC increased its position in shares of United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 33 shares during the last quarter. Finally, WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $524.28 on Monday. The business has a fifty day simple moving average of $490.39 and a two-hundred day simple moving average of $468.92. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $548.12. The company has a market capitalization of $22.98 billion, a price-to-earnings ratio of 18.79, a P/E/G ratio of 1.89 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the company earned $6.19 earnings per share. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $479.51, for a total value of $10,788,975.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $63,688.30. This trade represents a 98.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 318,870 shares of company stock worth $156,760,844. Insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on UTHR. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. HC Wainwright increased their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. TD Cowen lifted their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company upped their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $548.09.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.